Print

SCOLR Pharma, Inc. (DDD) Welcomes Clem Calabrese as Director of Field Sales  
5/1/2012 12:39:19 PM

BELLEVUE, Wash., May 1, 2012 /PRNewswire/ -- SCOLR Pharma, Inc. (OTCQB: SCLR) announced today that effective May 1, 2012 Clem Calabrese will be joining the SCOLR team as Director of Field Sales to lead our aggressive field sales & marketing activities. Clem brings a wealth of field sales experience to SCOLR and will be primarily responsible for working with our existing sales staff, the Emerson Group and our retail customers in order to ensure we aggressively grow our sales while providing the utmost in customer service.

Clem brings over 35 years of Branded and Store Brand Sales & Marketing experience with Major Consumer Products Companies.

Stephen Turner, President and CEO of SCOLR, said: "We are excited to have Clem join the SCOLR team. He is an impressive individual and will most assuredly provide us with additional sales opportunities as we continue to grow our consumer products sales. The depth of his relationships and contacts within the industry will enable SCOLR to continue the momentum created with our CDT® Controlled Release Technology with retailers."

About SCOLR Pharma:

Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT® platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT® drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

Forward looking statements:

Any statements made in this press release that relate to future plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements include statements regarding SCOLR's partners development of drug formulations, the results of a bioequivalence trials, anticipated future plans related to approval of drug formulations by the Food and Drug Administration, and the development and marketing of any drug formulations. Factors that could cause these forward-looking statements to differ from actual results include adverse regulatory determinations related to trials, competitive factors related to drug products, economic factors including partner's ability to finance the development and commercialization of any product, and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission. SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.

Contacts:
Investor Relations:
SCOLR Pharma, Inc.
425.368.1050

SOURCE SCOLR Pharma, Inc.


//-->